Clinical analysis of gastroenteropancreatic neuroendocrine tumor with liver metastasis, compared with primary hepatic neuroendocrine tumor

Ye, Shen; Chen, S; Zhang, W T; Ji, Yuan; Yu, Lei; Sun, Hui‐Chuan; Qiu, Shuang–Jian; Ren, Ning; Zhou, Jian

doi:10.4103/0973-1482.151532

Cited by 9 publications

(19 citation statements)

References 12 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, some studies have reported almost similar incidence in males and females[2,5,17,20,27-29]. The median age at diagnosis was 47 years in this study which was slightly lower compared to other studies, which have reported from 55-62 years[2,5,20,23,26]. …”

Section: Discussioncontrasting

confidence: 67%

“…It has been shown that the primary hepatic NEN to be predominantly a single lesion when compared to metastatic NEN[26]. In our study, a single lesion was identified in 10/79 cases (13%), of which a biopsy proven primary was confirmed in 7 cases and probable primary was identified by radiology in 2 and in one case, no primary was detected.…”

Section: Discussionmentioning

confidence: 45%

“…Male predilection has been shown in both metastatic and primary neuroendocrine tumors by Shen et al[26] and Shin et al[22] in their studies. However, some studies have reported almost similar incidence in males and females[2,5,17,20,27-29].…”

Section: Discussionmentioning

confidence: 99%

“…However, this duration was not adequate to derive any meaningful conclusion on long term outcomes in our study patients. Shen et al[26] have shown in their study on liver NEN, a better survival in low grade tumors as compared to high grade tumors. This could be due to the fact that this study included only liver resection cases but our study was done predominantly on biopsy samples and also due to lesser number of patients available for follow-up.…”

Section: Discussionmentioning

confidence: 99%

See 3 more Smart Citations

Neuroendocrine neoplasms of liver - A 5-year retrospective clinico-pathological study applying World Health Organization 2010 classification

Burad¹,

Kodiatte²,

Rajeeb³

et al. 2016

WJG

View full text Add to dashboard Cite

AIMTo study the clinicopathological characteristics of neuroendocrine neoplasms (NEN) on liver samples and apply World Health Organization (WHO) 2010 grading of gastroenteropancreatic (GEP) NEN.METHODSClinicopathological features of 79 cases of NEN of the liver diagnosed between January 2011 to December 2015 were analyzed. WHO 2010 classification of GEP NEN was applied and the tumors were graded as G1, G2 or G3. Two more categories, D1/2 (discordant 1/2) and D2/3 (discordant 2/3) were also applied. The D1/2 grade tumors had a mitotic count of G1 and Ki-67 index of G2. The D2/3 tumors had a mitotic count of G2 and Ki-67 index of G3. The follow up details which were available till the end of the study period (December 2015) were collected.RESULTSOf the 79 tumors, 16 each were G1 and G2, and 18 were G3 tumors. Of the remaining 29 tumors, 13 were assigned to D1/2 and 16 were D2/3 grade. Male preponderance was noted in all tumors except for G2 neoplasms, which showed a slight female predilection. The median age at presentation was 47 years (range 10-82 years). The most common presentation was abdominal pain (81%). Pancreas (49%) was the most common site of primary followed by gastrointestinal tract (24.4%) and lungs (18%). Radiologically, 87% of the patients had multiple liver lesions. Histopathologically, necrosis was seen in only D2/3 and G3 tumors. Microvascular invasion was seen in all grades. Metastasis occurred in all grades of primary NEN and the grades of the metastatic tumors and their corresponding primary tumors were similar in 67% of the cases. Of the 79 patients, 36 had at least one follow up visit with a median duration of follow up of 8.5 mo (range: 1-50 mo). This study did not show any impact of the grade of tumor on the short term clinical outcome of these patients.CONCLUSIONLiver biopsy is an important tool for clinicopathological characterization and grading of NEN, especially when the primary is not identified. Eighty-seven percent of the patients had multifocal liver lesions irrespective of the WHO grade, indicating a higher stage of disease at presentation. Follow up duration was inadequate to derive any meaningful conclusion on long term outcome in our study patients.

show abstract

Section: Discussioncontrasting

confidence: 67%

Section: Discussionmentioning

confidence: 45%

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

See 2 more Smart Citations

Neuroendocrine neoplasms of liver - A 5-year retrospective clinico-pathological study applying World Health Organization 2010 classification

Burad¹,

Kodiatte²,

Rajeeb³

et al. 2016

WJG

View full text Add to dashboard Cite

show abstract

“…8 Given the diversity of manifestations and the difficulty in diagnosis, neuroendocrine tumors can affect the life expectancy of those that suffer from them and require costly treatments. 9 …”

Section: Introductionmentioning

confidence: 99%

Prescription patterns of long-acting somatostatin analogues

Machado‐Alba

Machado‐Duque

2017

SAGE Open Medicine

View full text Add to dashboard Cite

Background:Acromegaly and endocrine tumors are uncommon morbidities that are currently treated with different drugs.Objective:To determine the prescription patterns of somatostatin analogues in patients affiliated with the Health System of Colombia.Methods:Retrospective cohort study of patients of any age and sex treated with octreotide or lanreotide between January 2011 and August 2015. Socio-demographic, clinical (indications) and pharmacological (comedications) variables were considered. Multivariate analysis was performed with SPSS 23.0.Results:We identified 289 patients, with a mean age of 56.6 ± 14.0 years and female predominance (59.5%), who underwent treatment during the 56 months of monitoring. Octreotide was used in 56.1% of cases, followed by lanreotide (43.9%), both at approved doses. We found that 4.5% of subjects changed from one drug to another over the course of therapy, which was associated with being diabetic and receiving insulin (odds ratio: 4.27; 95% confidence interval: 1.23–14.84; p = 0.014). The most common indications were acromegaly (52.2% of cases) followed by neuroendocrine tumors (15.9%). The most common comorbidities were hypertension (39.4% of cases), depression (27.3%), dyslipidemia (23.3%), diabetes mellitus (23.5%) and hypothyroidism (23.5%). Being male (odds ratio: 0.57; 95% confidence interval: 0.35–0.94; p = 0.029) and belonging to the age group between 45 and 65 years (odds ratio: 0.44; 95% confidence interval: 0.21–0.90; p = 0.024) were significantly associated with a lower risk of receiving comedications.Conclusion:Somatostatin analogues are being used at recommended doses, especially in patients with acromegaly and neuroendocrine tumors. Variables associated with change in therapy were identified.

show abstract

Hepatic neuroendocrine tumour: Apparent diffusion coefficient as a potential marker of prognosis associated with tumour grade and overall survival

et al. 2018

View full text Add to dashboard Cite

show abstract

Clinical analysis of gastroenteropancreatic neuroendocrine tumor with liver metastasis, compared with primary hepatic neuroendocrine tumor

Abstract: Surgery is an effective method for the treatment of hepatic NET; tumor grading is an important determinant factor of prognosis.

Cited by 9 publications

References 12 publications

Neuroendocrine neoplasms of liver - A 5-year retrospective clinico-pathological study applying World Health Organization 2010 classification

Neuroendocrine neoplasms of liver - A 5-year retrospective clinico-pathological study applying World Health Organization 2010 classification

Prescription patterns of long-acting somatostatin analogues

Hepatic neuroendocrine tumour: Apparent diffusion coefficient as a potential marker of prognosis associated with tumour grade and overall survival

Contact Info

Product

Resources

About